Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336075 | 1.00 | ALDH1A1 (0.37) | ALDH1A1SLC6A19CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9070664 | 0.84 | ALDH1A1 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25896074 | 0.84 | ALDH1A1 (0.34) | ALDH1A1SLC6A19CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22043583 | 0.82 | CHRNB2 (0.33) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23653179 | 0.82 | CHRNB2 (0.38) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15951606 | 0.82 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4ITK | |
| SCHEMBL12313552 | 0.81 | JAK3 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL14813244 | 0.80 | ALDH1A1 (0.34) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12831951 | 0.80 | JAK3 (0.33) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14813245 | 0.80 | ALDH1A1 (0.38) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4279486-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | Guangzhou Salustier Biosciences Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022148317-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 广州市力鑫药业有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022117051-A1 | MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885SLC6A19 2066/4885CHRNB2 3564/4885 |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885SLC6A19 3412/4885CHRNB2 4882/4885 |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 2810/4885SLC6A19 3172/4885CHRNB2 4357/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885SLC6A19 2066/4885CHRNB2 3564/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885SLC6A19 3412/4885CHRNB2 4882/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885SLC6A19 2066/4885CHRNB2 3564/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885SLC6A19 2066/4885CHRNB2 3564/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | ALDH1A1 2334/4885SLC6A19 2179/4885CHRNB2 4163/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885SLC6A19 3412/4885CHRNB2 4882/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | ALDH1A1 3496/4885SLC6A19 2134/4885CHRNB2 2885/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885SLC6A19 3412/4885CHRNB2 4882/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885SLC6A19 3412/4885CHRNB2 4882/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885SLC6A19 4877/4885CHRNB2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.